Role of losartan in decreasing uric acid levels at JPMC.

Objective: To determine the mean change in uric acid level after use of losartan in hypertensive patients at tertiary care hospital. Study Design: Quasi Experimental study. Setting: Department of Medicine at JPMC. Period: 18/01/2024 to 17/07/2024. Methods: 100 eligible patients were selected written informed consent was given by each patient. The baseline assessments included demographics, medical history, and serum uric acid levels. At four, eight, and twelve weeks following therapy, patients were observed to assess changes in uric acid levels, medication adherence, and adverse events. Data was gathered using a prepared proforma, ensuring comprehensive documentation for each study component. Results: Participants in the study were mostly between the ages of 41 and 80 (91%), with a mean age of 57.89 years (SD = 11.15). Measurements included height (173.42 cm ± 9.32), weight (76.99 kg ± 9.51), BMI (25.83 ± 2.21), duration of hypertension (26.00 months ± 11.80), and serum uric acid levels at baseline (7.38 mg/dL ± 0.78), 4 weeks (6.91 mg/dL ± 0.52), 8 weeks (6.70 mg/dL ± 0.52), and 12 weeks (6.09 mg/dL ± 0.25). 55% of the population was male and 45% was female, and 63% of them lived in urban and 37% in rural areas. In terms of employment status, 62% were employed while 38% were unemployed, and 38% reported having diabetes. Serum uric acid levels significantly decreased with losartan, going from 7.38 mg/dL (SD = 0.78) at the beginning to 6.09 mg/dL (SD = 0.25) after 12 weeks (p = 0.001), indicating that hypertension-related hyperuricemia was effectively controlled. Conclusion: This result highlights losartan's potential usefulness in treating hyperuricemia linked to hypertension by indicating that it is effective in lowering serum uric acid levels during the course of treatment.